Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;9(3):243-253.
doi: 10.1530/EC-20-0035.

SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors

Solène Castellnou  1   2 , Alexandre Vasiljevic  2   3   4 , Véronique Lapras  5 , Véronique Raverot  6 , Eudeline Alix  7 , Françoise Borson-Chazot  1   2 , Emmanuel Jouanneau  2   4   8 , Gérald Raverot  1   2   4 , Hélène Lasolle  1   2   4
Affiliations

SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors

Solène Castellnou et al. Endocr Connect. 2020 Mar.

Abstract

Objective: Somatostatin receptor type 5 (SST5) is inconsistently expressed by corticotroph tumors, with higher expression found in corticotropinomas having ubiquitin-specific protease 8 (USP8) mutations. Aims were to study the correlation between characteristics of corticotropinomas and SST5 expression/USP8 mutation status and to describe the response to pasireotide in five patients.

Design: Retrospective cohort study.

Methods: Clinico-biochemical, radiological and pathological data of 62 patients, operated for a functioning or silent corticotropinoma between 2013 and 2017, were collected. SST5 expression was measured by immunohistochemistry (clone UMB-4, Abcam, IRS > 1 being considered positive), and Sanger sequencing was performed on 50 tumors to screen for USP8 mutations.

Results: SST5 expression was positive in 26/62 pituitary tumors. A moderate or strong IRS was found in 15/58 corticotropinomas and in 13/35 functioning corticotropinomas. Among functioning tumors, those expressing SST5 were more frequent in women (22/24 vs 9/15, P = 0.04) and had a lower grade (P = 0.04) compared to others. USP8 mutations were identified in 13/50 pituitary tumors and were more frequent in functioning compared to silent tumors (11/30 vs 2/20, P = 0.05). SST5 expression was more frequent in USP8mut vs USP8wt tumors (10/11 vs 7/19, P = 0.007). Among treated patients, normal urinary free cortisol levels were obtained in three patients (IRS 0, 2 and 6), while a four-fold decrease was observed in one patient (IRS 4).

Conclusion: SST5 expression appears to be associated with functioning, USP8mut and lower grade corticotropinomas. A correlation between SST5 expression or USP8mut and response to pasireotide remains to be confirmed.

Keywords: SST5; USP8; corticotroph pituitary tumors; pasireotide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ACTH expression in SST5 positive and negative corticotroph tumors according to the functional status. P-value calculated using Wilcoxon rank test.
Figure 2
Figure 2
SST5 expression in USP8mut or USP8wt corticotroph tumors. mut, mutant; wt, wild-type. P-value calculated using Wilcoxon rank test.
Figure 3
Figure 3
Evolution of 24-h UFC after introduction of pasireotide in patients A to E (left) and SST5 immunohistochemistry (original magnification ×200) (right). 24-h UFC, 24-h urinary free cortisol; IRS, immunoreactive score. Dotted lines on graphs represent 24-h-UFC norm, and daily dosage of pasireotide is represented below each graph, expressed in mg. Photographs were taken in the most immunoreactive area and are not representative of the whole tumor.
See this image and copyright information in PMC

References

    1. Ntali G, Grossman A, Karavitaki N. Clinical and biochemical manifestations of Cushing’s. Pituitary 2015. 18 181–187. (10.1007/s11102-014-0631-4) - DOI - PubMed
    1. van Haalen FM, Broersen LHA, Jorgensen JO, Pereira AM, Dekkers OM. Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. European Journal of Endocrinology 2015. 172 R143–R149. (10.1530/EJE-14-0556) - DOI - PubMed
    1. Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing’s disease. Pituitary 2015. 18 188–194. (10.1007/s11102-015-0645-6) - DOI - PMC - PubMed
    1. Guttenberg KB, Mayson SE, Sawan C, Kharlip J, Lee JY, Martinez-Lage M, Loevner LA, Ewanichak J, Grady MS, Snyder PJ. Prevalence of clinically silent corticotroph macroadenomas. Clinical Endocrinology 2016. 85 874–880. (10.1111/cen.13146) - DOI - PubMed
    1. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. European Journal of Endocrinology 2010. 163 35–43. (10.1530/EJE-10-0076) - DOI - PubMed